featured
Ibrutinib Plus Immunochemotherapy With or Without ASCT vs Immunochemotherapy and ASCT for Previously Untreated Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Lancet 2024 May 02;[EPub Ahead of Print], M Dreyling, J Doorduijn, E Giné, M Jerkeman, J Walewski, M Hutchings, U Mey, J Riise, M Trneny, V Vergote, O Shpilberg, M Gomes da Silva, S Leppä, L Jiang, S Stilgenbauer, A Kerkhoff, RD Jachimowicz, M Celli, G Hess, L Arcaini, C Visco, T van Meerten, S Wirths, PL Zinzani, U Novak, P Herhaus, F Benedetti, K Sonnevi, C Hanoun, M Hänel, J Dierlamm, C Pott, W Klapper, D Gözel, C Schmidt, M Unterhalt, M Ladetto, E HosterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.